[Research progress of treatment strategies for choroidal neovascularization secondary to pathological myopia].

Pathological myopia refers to high myopia with fundus pathological changes. Choroidal neovascularization is one of its serious complications, and also the main cause of visual loss. Currently, the first-line treatment is anti-VEGF treatment, with good efficacy, high safety, good prognosis, and other advantages of vision. Commonly used anti-VEGF drugs include bevacizumab, ranibizumab, aflibercept, and conbercept. The main treatment strategies include 1+pro re nata and 3+pro re nata, and the standard of REPAIR test is often used to evaluate the re-injection. This article reviews the advantages of anti-VEGF therapy, drug selection, treatment strategy, and re-injection criteria. (Chin J Ophthalmol, 2019, 55:791-795).病理性近视眼指高度近视眼伴眼底病理性改变，继发脉络膜新生血管是其严重并发症之一，也是导致视力下降的主要因素。目前一线治疗方法是抗血管内皮生长因子（VEGF）治疗，具有疗效确定、安全性高、视力预后较好等优势。常用抗VEGF药物包括贝伐单克隆抗体、雷珠单克隆抗体、阿柏西普、康柏西普。主要治疗方案包括1+ pro re nata（PRN）和3+PRN，临床多以雷珠单克隆抗体治疗病理性近视眼继发脉络膜新生血管的Ⅱ期临床试验提出的标准对再注射进行评估。本文针对抗VEGF治疗的优势、药物选择、治疗方案及再注射标准，对相关研究进展进行综述，以期为临床治疗提供参考。（中华眼科杂志，2019，55：791-795）.